Adipotide vs AOD-9604

Adipotide wins for fat-loss potency, especially targeting visceral and stubborn adipose tissue, and produces rapid, short-course results when other tools plateau. Mechanistically unique with significant effects validated in primate models — but demands vigilant renal monitoring due to proximal tubule accumulation.

AOD-9604 wins for side-effect profile, long-term safety, ease of stacking, and zero impact on glucose, IGF-1, or sex hormones. It's the low-drama, zero-bloodwork adjunct that slots into almost any fat-loss phase without the risk profile or renal flag of Adipotide.

Pick Adipotide if:

• Visceral fat reduction is the primary goal, especially after GLP-1/deficit stalls
• Targeting difficult, diet-resistant depots (e.g., belly, organ fat) is a priority
• Short, finite cycles are preferred over long-term daily administration
• There's willingness to run aggressive renal bloodwork and accept higher risk for greater effect
• Cleaning up metabolic damage post heavy GH/slin cycles

Pick AOD-9604 if:

• A side-effect-free, mild fat-loss adjunct is needed (women and men run same protocol)
• The goal is steady lipolysis during a cut or alongside GLP-1s without glucose/IGF-1 disruption
• GH or secretagogue stacks need an extra nudge for stubborn fat
• Compounds requiring frequent bloodwork or with organ risk are off the table
• A plug-and-play peptide, safe for longer-term or repeat runs, is preferred